5.30

0.19% 0.010

After Hours: 5.28 -0.02 -0.38%

Xeris Biopharma Holdings Inc (XERS)

Overview News Price History Option Chain Financials Discussions Forecast

Xeris Biopharma Holdings Inc stock is traded at $5.30, with a volume of 2.36M. It is up +0.19% in the last 24 hours and down -20.42% over the past month. Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Previous Close:

$5.29

Open:

$5.34

24h Volume:

2.36M

Relative Volume:

1.16

Market Cap:

$913.89M

Revenue:

$291.85M

Net Income/Loss:

$554.00K

P/E Ratio:

-697.37

EPS:

-0.0076

Net Cash Flow:

$27.93M

1W Performance:

-2.39%

1M Performance:

-20.42%

6M Performance:

-32.48%

1Y Performance:

-9.71%

1-Day Range:

$5.25

$5.475

1-Week Range:

$5.25

$5.64

52-Week Range:

$3.805

$10.08

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Name

Xeris Biopharma Holdings Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

844-445-5704

Address

1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL

Employee

435

Twitter

@XerisPharma

Next Earnings Date

2024-12-08

Latest SEC Filings

XERS's Discussions on Twitter

Compare XERS vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XERS Xeris Biopharma Holdings Inc	5.30	912.16M	291.85M	554.00K	27.93M	-0.0076
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Overweight
Aug-12-25	Resumed	H.C. Wainwright	Buy
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Mar-28-24	Initiated	Oppenheimer	Outperform
Aug-28-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Craig Hallum	Buy
Nov-17-21	Initiated	SVB Leerink	Outperform
Oct-29-21	Initiated	H.C. Wainwright	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-18-20	Initiated	Piper Sandler	Overweight
Jul-16-18	Initiated	Jefferies	Buy
Jul-16-18	Initiated	Leerink Partners	Outperform
Jul-16-18	Initiated	RBC Capital Mkts	Outperform

View All

Xeris Biopharma Holdings Inc Stock (XERS) Latest News

Mar 21, 2026

Market Review: Can Xeris Biopharma Holdings Inc keep up with sector leaders - baoquankhu1.vn

Mar 21, 2026

Xeris Biopharma stock faces analyst scrutiny amid pipeline delays and biotech volatility - AD HOC NEWS

Mar 21, 2026

Mar 19, 2026

Barclays reiterates Xeris Pharmaceuticals stock rating on sales outlook By Investing.com - Investing.com Canada

Mar 19, 2026

Mar 17, 2026

350,168 Shares in Xeris Biopharma Holdings, Inc. $XERS Purchased by Granahan Investment Management LLC - MarketBeat

Mar 17, 2026

Mar 16, 2026

Xeris Biopharma (NASDAQ: XERS) officer boosts stake via option exercise - Stock Titan

Mar 16, 2026

Divisadero Street Capital Management LP Takes $3.31 Million Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat

Mar 16, 2026

Mar 13, 2026